GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

LAVA-1207 overview

LAVA-1207 is under development for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It is administered through intravenous route. The therapeutic candidate comprises single domain bi-specific antibody that acts by targeting T cell receptor of Vgamma9Vdelta2 T-cells and PSMA. It is being developed based on bi-specific gamma delta T cell engager (bsTCEs) platform and Gammabody platform.

LAVA Therapeutics overview

LAVA Therapeutics is a biotechnology company. It is engaged in developing immune oncology biopharmaceuticals products. Its proprietary V?9Vd2 T-cell engager candidates bind to the conserved (monomorphic) T-cell receptor of V?9Vd2 T-cells which exhibit potent cytotoxicity, interferon-gamma secretion and HLA-unrestricted tumor cell killing capabilities for alpha-beta-T cells advancing the development of adaptive immune responses for selected tumor targets. Lava Therapeutics licenses its V?9Vd2 T-cell immune oncology assets from the VU University Medical Center in Amsterdam. It seeks to work in partnerships or collaborations in licensing its products and proprietary technologies. The company is funded by Biox Biosciences BV, and Lupus Ventures BV. Lava Therapeutics is headquartered in s-Hertogenbosch, Noord Brabant, the Netherlands.

For a complete picture of LAVA-1207’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.